Envision Sciences' novel biomarker discovery program has identified a fundamental change in the cell biology of prostate cancer.
Envision Sciences have used this cutting-edge discovery to identify three biomarkers that define prostate cancer pathogenesis and developed accurate tests to improve clinical practice. Prostate cancer is the second most common form of cancer in men worldwide. Envision Sciences' is developing a complete pathology solution for prostate cancer, involving two blood tests that will be used to detect the cancer and provide an indication of prognosis, as well as tissue biopsy tests to confirm the diagnosis and prognosis.
The high sensitivity (≥95%) and specificity (≥95%) of these biomarker tests will significantly reduce reporting error and increase the reliability of prostate cancer testing. Envision Sciences is a cell biology company with a primary focus on diagnostics, prognostics, live cell imaging and identification of targets for therapeutic treatments. By interrogating cell biology pathways, which define the primary pathogenesis of cancer, Envision Sciences has developed clinical tests that are objective, verifiable and quantifiable.
Envision Science' goal is to lead the way in providing high specificity and sensitivity outcomes across various forms of cancer. Envision Sciences research team is located in the University of South Australia Cancer Research Institute
BTB Round: Two
State: South Australia
Project Partner: University of South Australia
- MTPConnect Grant: $1,000,000
- Industry Contribution: $1,333,330
Duration: September 2020 – June 2022
Visit Envision Sciences Pty Ltd for more information.
Contact: Prof Doug Brooks